RxDoctor Payments Data

Karen Shainsky, DO

Rheumatology · West Hollywood, CANPI 1740409283

Payments from drug & device makers

$22,002in general payments, 2019–2025

Across 982 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • Novartis$2K
  • Pacira Pharmaceuticals Incorporated$2K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • GSK$1K
  • plus $9K from 54 others

What the payments were for

  • Travel & lodging$1,1745%
  • Food & beverage$20,63894%
  • Education$1891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)240$4,670
Novartis130$2,140
Pacira Pharmaceuticals Incorporated9$1,570
Lilly USA, LLC62$1,420
AbbVie(2 entities)62$1,398
GSK61$1,342
IBSA Pharma Inc.49$857
Radius Health, Inc.25$687
Johnson & Johnson(3 entities)26$685
Vifor Pharma, Inc.26$571
Amarin Pharma, Inc.25$520
Mallinckrodt Hospital Products Inc.15$500
Fidia Pharma USA Inc.24$471
Novo Nordisk20$434
AstraZeneca19$404
Pfizer12$307
UCB, Inc.9$289
ANI Pharmaceuticals, Inc.11$285
Edwards Lifesciences9$282
Bayer12$277
Nestle Healthcare Nutrition Inc.11$257
Hikma Pharmaceuticals USA16$252
Eisai Inc.8$169
Ironwood Pharmaceuticals, Inc7$154
Sanofi6$124
Aimmune Therapeutics, Inc.5$123
Avanos Medical6$110
Genentech USA, Inc.6$106
Merck4$103
Biohaven Pharmaceutical Holding Company Ltd.5$101
E.r. Squibb & Sons, L.L.C.5$100
Sumitomo Pharma America, Inc.4$99
Esperion Therapeutics, Inc.4$77
Sanofi-aventis U.S. LLC3$74
Mallinckrodt Enterprises LLC3$71
Takeda Pharmaceuticals U.S.A., Inc.3$70
Shield Therapeutics Inc3$70
Arbor Pharmaceuticals, Inc.4$69
GRT US Holding, Inc.2$62
Vivus LLC3$55
Sobi, Inc2$52
Pacira Therapeutics, Inc.2$52
Boehringer Ingelheim2$49
Heartflow, Inc.2$47
Kowa Pharmaceuticals America, Inc.2$46
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$45
Alnylam Pharmaceuticals Inc.2$44
Celltrion USA Inc.1$37
Scilex Pharmaceuticals Inc.2$36
Zimmer Biomet1$31
Fresenius Kabi USA, LLC1$27
Aurinia Pharma U.S., Inc.1$27
Medtronic1$25
Mylan Specialty L.p.1$23
Tactile Systems Technology Inc1$20
Biohaven Pharmaceuticals, Inc.1$19
Ferring Pharmaceuticals Inc.1$18
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$17
Idorsia Pharmaceuticals US Inc1$14
Medicure Pharma Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,002 in reported general payments places this provider in the 75th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$1,551,007
Medicare patients
910
Services billed
60,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProliaDenosumab308$508,216
OrenciaAbatacept/Maltose66$372,723
Diclofenac Sodium614$367,935
Cosentyx Sensoready (2 Pens)Secukinumab37$273,579
Evenity (2 Syringes)Romosozumab-Aqqg102$244,478
Simponi AriaGolimumab20$160,423
Diclofenac Epolamine253$150,013
OrenciaAbatacept24$134,492
MounjaroTirzepatide123$133,245
Humira(Cf) PenAdalimumab19$129,412
RayosPrednisone21$100,567
Orencia ClickjectAbatacept18$98,660
EnbrelEtanercept12$88,271
Taltz SyringeIxekizumab12$81,155
RemicadeInfliximab17$74,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia, Evenity (2 Syringes), Rayos, Enbrel$4,670$941,533443 claims
E.r. Squibb & Sons, L.L.C.Orencia, Orencia$100$507,21690 claims
Johnson & JohnsonSimponi Aria, Remicade$685$234,53737 claims
Lilly USA, LLCMounjaro, Cymbalta$1,420$143,801134 claims
IBSA Pharma Inc.Licart, Flector$857$70,50678 claims
PfizerXeljanz$307$68,29312 claims
Novo NordiskOzempic$434$35,66838 claims
Scilex Pharmaceuticals Inc.Colchicine$36$4,812260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 rheumatology providers in California.

Other rheumatology in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →